PT-141 calculator
This is a research reference, not a product for sale or a dosing recommendation. No amount is selected for PT-141. A listed name does not mean it is supplied in a vial or should be injected.
About PT-141
PT-141 is the development name associated with bremelanotide, a synthetic melanocortin-receptor agonist peptide derived from the melanocortin research compound Melanotan II. Its pharmacology involves central melanocortin signaling, unlike phosphodiesterase-5 inhibitors, which act through a different pathway. Bremelanotide is an FDA-approved prescription drug only in a specific formulation and indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Approval of that product does not establish other PT-141 preparations or uses.
At a glance
- Class
- Synthetic melanocortin-receptor agonist peptide; bremelanotide is the approved drug name.
- Studied mechanism
- Acts on melanocortin receptors, including central pathways implicated in sexual desire.
- Regulatory context
- FDA approval applies to Vyleesi (bremelanotide) for acquired, generalized HSDD in premenopausal women—not to all products labeled PT-141 or other indications.
Blank arithmetic calculator
For independently verified inputs, concentration equals entered vial amount in mg divided by added liquid in mL. Entered requested mg divided by concentration gives mL; multiplying mL by the actual syringe markings per mL gives units. Enable JavaScript to use the calculator. This math does not establish that a compound is suitable for injection.
Common questions
Is PT-141 FDA-approved?
Bremelanotide, the drug associated with the PT-141 name, is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That approval is specific to the prescription product and indication.
How does bremelanotide's mechanism differ from PDE5 inhibitors?
Bremelanotide acts through melanocortin-receptor signaling, including central pathways. PDE5 inhibitors act through a separate cyclic-GMP pathway; the two drug classes are not interchangeable.
Research & references
- Vyleesi (bremelanotide) FDA label
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials — PubMed
Related compound pages
Read the math guides · Browse all compound names